Berkshire Biomedical announced today that it appointed John E. Timberlake as its new president and CEO.
Dallas-based Berkshire Biomedical, which develops a virtual care prescription drug delivery and management system, also added Timberlake to its advisory board, according to a news release.
The COPA system is designed to offer virtual care delivery using technology combined with data along with medication self-administration and adherence.
“We are delighted to welcome John to the Berkshire Biomedical team. His extensive leadership experience within the healthcare industry will be instrumental as we move toward the introduction of the COPA system, our virtual care prescription drug delivery and management solution,” Berkshire Biomedical co-founder & chairman Thomas M. Rouse said in the release. “John’s experience with early-stage team building is an excellent fit for Berkshire at this stage of our growth. John’s in-depth industry knowledge and network will be particularly important as we continue work to identify and execute collaborations with strategic partners and we transition from a product development company to a product marketing company.”
Timberlake, a veteran of more than 30 years in the life sciences space, most recently served as CEO, president and board member at Valeritas, having worked at the company for 14 years before executing its sale to Zealand Pharma in April 2020.
He also held varying leadership roles at Sanofi and its predecessor companies, including a number of key positions in creating the company’s diabetes franchise.
“This is an exciting time to join Berkshire Biomedical as the COPA system addresses the intersection of two great needs in the healthcare ecosystem — the drive for virtual care led by technology and data and the imperative to improve medical adherence,” Timberlake said. “I look forward to bringing my years of experience to bear in advancing the commercialization of this innovative system both through strategic partnerships and through our own channels. I am confident we will be successful bringing this potentially game-changing virtual care prescription drug delivery and management system to the market as we position Berkshire to be a leader in healthcare innovation.”
